NEW ONSET OF NAIL PSORIASIS AFTER MRNA COVID-19 VACCINE: A CASE REPORT
Journal of IMAB - Annual Proceeding (Scientific Papers)
; 28(1):4289-4291, 2022.
Article
in English
| EMBASE | ID: covidwho-1798799
ABSTRACT
Currently in Bulgaria the two messenger RNA vaccines used to vaccinate the population against COVID-19 are Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY) and Moderna COVID-19 Vaccine. We present a case of a patient with palmoplantar form of psoriasis (in remission in the last 2 years), who has an attack of psoriasis of the nails, which began two weeks after the second dose of Pfizer-BioNTech COVID-19 Vaccine. Within the next two months, onychopathy of the nails of the ten fingers developed with the manifestation of almost all known psoriatic changes in the nail bed and nail matrix. The toenails are not affected. Topical therapy with calcipotriol/betamethasone ointment under occlusive dressings was prescribed for two months. The monitoring continues.
adult; adverse drug reaction; article; case report; clinical article; drug combination; female; finger; human; male; nail bed; nail disease; nail psoriasis; occlusive dressing; ointment; psoriasis; Psoriasis Severity Index; pustulosis palmoplantaris; remission; side effect; toe nail; topical treatment; betamethasone; calcipotriol; RNA vaccine; tozinameran
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Case report
Topics:
Vaccines
Language:
English
Journal:
Journal of IMAB - Annual Proceeding (Scientific Papers)
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS